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TO THE EDITOR
Chediak–Higashi syndrome (CHS
(OMIM 214500)) is a rare autosomal
recessive disorder caused by mutations
in the CHS1 gene. Clinical character-
istics can include oculocutaneous hy-
pomelanosis, bleeding, bruising,
infections, hemophagocytic lympohis-
tiocytosis and late-onset progressive
neurological impairment. (White and
Clawson, 1979; Nagle et al., 1996;
Fukai et al., 1996; Introne et al., 1999;
McVey Ward et al., 2002; Clark and
Griffiths, 2003; Gunay-Aygun et al.,
2004).
The function of the CHS1 protein is
largely unknown, but CHS patients do
manifest enlarged lysosomes and lyso-
some-related organelles in all cell types
(White and Clawson, 1979; Burkhardt
et al., 1993; Zhao et al., 1994; Introne
et al., 1999). Recent functional studies
on different CHS1 domains and known
interacting partners of CHS1, including
v-SNAREs and t-SNARES, signaling
protein 14-3-3, casein kinase II, and
Hrs, strongly suggest a role for CHS1 in
determining organelle size by control-
ling membrane fission and/or fusion
events (Tchernev et al., 2002; McVey
Ward et al., 2003).
Various CHS clinical phenotypes
have been correlated with molecular
genotypes where loss-of-function muta-
tions are associated with severe early-
onset CHS characterized by fatal infec-
tions and hemophagocytic lympohistio-
cytosis, whereas missense mutations
are associated with milder, late-onset
CHS with slowly progressive neurologi-
cal impairment, or an adolescent
form with infections but no hemopha-
gocytic lympohistiocytosis (Karim et al.,
2002).
Here, we report the cell biological
characteristics of various cell types
from two patients on opposite ends of
the CHS clinical spectrum, one bearing
two new CHS1 mutations. Both patients
were enrolled in a protocol approved
by the NHGRI Institutional Review
Board, and written, informed consent
was obtained. The study was conducted
according to the Declaration of Helsin-
ki Principles. The severe early-onset
form of CHS was represented by patient
CHS4; the clinical diagnosis and mole-
cular findings were reported previously
(Zarzour et al., 2005). The milder adult
late-onset of CHS was represented by
patient CHS6, whose hair was brown-
black and whose irides were deep blue,
with transillumination. He had dense
bodies in some platelets (Figure 1a and
b), and a normal number of natural
killer cells. The patient also had numer-
ous slightly enlarged granules in neu-
trophils and eosinophils (Figure 1c–f)
and absence of significant infections or
lymphohistiocytosis, but late-onset,
progressive neurological impairment.
Interestingly, these clinical findings
resemble the recently described N-
ethyl-N-nitrosourea (ENU)-induced
homozygous LYSTIng3618 mouse that
manifests age-dependent neurological
impairment and Purkinje cell degenera-
tion (Rudelius et al., 2006). Mutation
analysis for CHS6 revealed a new
truncating frameshift mutation
c.2413delG, p.E805fsX806 in exon 6,
and a novel missense mutation
c.10127A4G, p.N3376S in exon 44
located in the CHS protein’s highly
conserved BEACH motif. This motif
characterizes a protein family crucial
for vesicle trafficking, membrane dy-
namics, and receptor signaling (Jogl
et al., 2002; De Lozanne, 2003). Muta-
tion analysis on 50 healthy individuals
confirmed that c.10127A4G is not a
common polymorphism. This is the
first report of an adult-onset CHS
patient with both a severe and mild
mutation.
We investigated whether the clinical
and molecular correlations in different
forms of CHS held true on the cell
biological level. Laser scanning con-
focal microscopy of fibroblasts stained
with the lysosomal marker lysosomal
associated membrane protein-1 (LAMP-1)
(H4A3; Developmental Studies Hybri-
doma Bank, University of Iowa, Iowa
City, IA) showed normal sized lyso-
somes distributed in the perinuclear
and peripheral region in control cells
(Figure 1g). CHS4 fibroblasts exhibited
normal and giant lysosomes clustered
around the nucleus (Figure 1h), consis-
tent with findings in beige mouse
fibroblasts (Burkhardt et al., 1993).
CHS6 fibroblasts exhibited an attenu-
ated phenotype with a mixture of
normal and slightly enlarged lysosomes
in the perinuclear area and some
peripheral distribution (Figure 1i). To
study lysosome-related organelles in
CHS, we focused on melanosomes.
Laser scanning confocal microscopy
was used to evaluate the distribution
of the melanosome-specific proteins
Pmel17 and tyrosinase-related protein
1 (Tyrp1). In control melanocytes,
Pmel17 (HMB45, Lab Vision, Fremont,
CA) showed a typical melanosomal
peripheral punctuate distribution with
accumulation in the actin-rich dendritic
tips (Figure 1j). In CHS4, Pmel17
mainly occupied granules scattered
throughout the cell body and dendrites;
accumulation in the dendritic tips was
never observed (Figure 1k). For CHS6,
Pmel17 distribution resembled the pat-
tern in control melanocytes, with some
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concentration in the dendritic tips
(Figure 1l). In control melanocytes,
Tyrp1 (MEL5, Signet Laboratories, Ded-
ham, MA) resembled Pmel17 localiza-
tion with accumulation in dendritic tips
(Figure 1m). In contrast, CHS4 melano-
cytes showed a predominant vesicular
perinuclear distribution of Tyrp1 with
some dendritic localization and no
accumulation in the dendritic tips
(Figure 1n). In CHS6 melanocytes,
Tyrp1 was distributed throughout the
cell and dendrites with some localiza-
tion in the tips (Figure 1o).
To study the morphology, localiza-
tion and pigment content of melano-
somes in detail, we used light
microscopy, routine electron micro-
scopy (EM), and 3,4-dihydroxyphenyla-
lanine (DOPA) EM. Control melano-
cytes exhibited a primarily peripheral
distribution of melanosomes with clear
localization in dendrites and the den-
dritic tips (Figure 2a, arrows), and
different stages of normal sized pig-
mented melanosomes were observed
on the ultrastructural level (Figure 2b).
The majority of CHS4 melanosomes
localized in the cell body and dendrites
but there was no accumulation in the
tips (Figure 2e); melanosomes were
enlarged and irregularly shaped with
focal pigment deposits (Figure 2f, ar-
rows). CHS6 melanocytes showed an
apparently normal localization of spar-
sely pigmented melanosomes in den-
drites, with minor accumulation in the
tips (Figure 2i). Ultrastructural data
showed virtual absence of melanin
deposits within round-shaped melano-
somes (Figure 2j, asterisk) and an
occasional giant melanosome (Figure
2j, arrow). DOPA EM was used to study
the localization of tyrosinase. Compared
with control melanocytes (Figure 2c and
d), both CHS4 and CHS6 melanocytes
revealed more DOPA-positive 50 nm
vesicles distributed throughout the cell
body and dendrites (Figure 2h and l,
arrows). Numerous DOPA-positive tubu-
lar elements were present within the
majority of CHS4 melanocytes (inset in
Figure 2g), and significant focal melanin
depositions were observed within the
giant melanosomes (Figure 2h, asterisk).
In contrast, DOPA-positive tubular
structures in CHS6 were sparse and
very little DOPA reaction-product accu-
mulated within melanosomes (Figure 2l
asterisk).
The cellular findings on platelets,
neutrophils, fibroblasts, and melano-
cytes show the cell biological charac-
teristics of a patient with late-onset CHS
for the first time. Comparison with cell
biological findings of severe early-onset
CHS allows us to draw several conclu-
sions. CHS should be part of the
differential diagnosis of patients with
adult-onset neurodegenerative disease
of unknown etiology. The presence of
slightly enlarged neutrophil granules
(Figure 1d) will make the CHS diag-
nosis, even in the absence of serious
infections. Some CHS platelets can
have dense bodies, whereas others do
not (Figure 1b), explaining contradic-
tory reports regarding the presence or
g
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Figure 1. Lysosomes and lysosome-related organelles in cultured CHS cells. (a) Whole mount EM of
control platelets with dense bodies (arrows). (b) Some CHS6 platelets have no dense bodies
(asterisk). (c) Control neutrophil. (d) CHS6 neutrophil with larger granules. (e) EM of a
CHS6 neutrophil with large inclusions (arrows). (f) EM of a myeloperoxidase staining of a
CHS6 eosinophil with large granules (arrowheads). (g) LAMP1 in control fibroblasts, (h) LAMP1
in CHS4 fibroblasts shows some enlarged lysosomes. (i) LAMP1 in CHS6 fibroblasts shows slightly
enlarged lysosomes.(j and m) Control melanocytes stained for Pmel17 and Tyrp1, respectively.
(k) Pmel17 in CHS4 melanocytes localizes into the perinuclear and dendritic area but not
to dendritic tips. (l) Pmel17 in CHS6 melanocytes shows a peripheral localization with some
accumulation in dendritic tips. (n) Tyrp1in CHS4 melanocytes accumulate in the perinuclear
area with some dendritic localization. (o) Tyrp1 in CHS6 melanocytes is intermediate
between that of normal control and CHS4 melanocytes. All the cells were co-stained for actin
with BODIPY 558/568 phalloidin. Bar¼20mm. All images are 1D projections of confocal
z-sections.
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absence of dense granules in CHS
(White, 2003; Nurden, 2005). Finally,
the differences in cell biological char-
acteristics of various cell types derived
from patients with different forms of
CHS fully support a molecular, clinical,
and cellular genotype–phenotype cor-
relation. In addition, cells derived from
CHS patients might help identify the
origin of giant organelles and deter-
mine, which domains and motifs in
CHS1 might be essential for proper
neurological development yet dispen-
sable for immune function.
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Figure 2. Melanosomes in Cultured CHS melanocytes. (a) Bright field microscopy of control
melanocytes with pigment accumulation in the dendritic tips compared with the melanosomes
of CHS4 melanocytes (e) and the practically unpigmented melanosomes with localization in the
dendrites in CHS6 melanocytes (i), bar¼ 20mm. (b) Routine EM of control melanocytes with
melanosomes at different stages of maturation (II, III, and IV) compared with the large, sparsely pigmented
melanosomes of CHS4 melanocytes (f, arrows) and the poorly pigmented melanosomes of CHS6
melanocytes (j, asterisk) with an occasional larger melanosome (j, arrow). (c and d) DOPA EM of
control melanocytes with melanosomes distributed throughout (c) the cell body and (d) dendrites,
(g and h asterisk) compared with the sparse, enlarged melanosomes with focal pigment deposits
in CHS4 melanocytes. (k and l) CHS6 melanocytes show abundant localization in the dendritic area.
(h and l, arrows) 50 nm vesicles in CHS4 and CHS6 melanocytes. (g, inset) DOPA-positive
tubular element in CHS4 melanocytes. Bar¼ 1.0 mm for b, f, and j. Bar¼ 8.0mm for c, g, and k.
Bar¼2.5 mm for d, h, and l.
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